arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

AIM ImmunoTech Inc.

AIM
$0.21 0.00 (-2.24%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

AIM ImmunoTech Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $3.6M
Dividend Yield
Revenue Growth 4.0%
Op. Margin
ROIC -24.4%
FCF / Share $-0.27
Trailing P/E
Price / Book 0.8x
FCF Yield
Debt / Equity 0.47
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$26.00K
↑ +4.0%
Net Income Profit after all expenses
$-3.02M
↑ +18.4%
FCF / Share Free cash flow per share
$-0.27
↑ +57.1%
Long-Term Debt Long-term obligations
$3.62M
↓ -14.1%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Financial Health
63
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters